PubMed

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.

Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR.

Leuk Res. 2009 Sep 11. [Epub ahead of print]PMID: 19748672 [PubMed - as supplied by publisher]Related articles

Novel microtubule-targeting agents - the epothilones.

Cheng KL, Bradley T, Budman DR.

Biologics. 2008 Dec;2(4):789-811.PMID: 19707459 [PubMed - in process]Related articlesFree article

The hedgehog pathway as a therapeutic target for treatment of breast cancer.

Barginear MF, Leung M, Budman DR.

Breast Cancer Res Treat. 2009 Jul;116(2):239-46. Epub 2009 May 29. Review.PMID: 19479372 [PubMed - indexed for MEDLINE]Related articles

Adjuvant chemotherapy for early breast cancer in the elderly.

Leung M, Shapira I, Bradley T, Budman DR.

Curr Treat Options Oncol. 2009 Aug;10(3-4):144-58. Epub 2009 Apr 10.PMID: 19360475 [PubMed - in process]Related articles

Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.

Kim BH, Bradley T, Tai J, Budman DR.

Oncology. 2009;76(4):231-8. Epub 2009 Feb 25.PMID: 19246947 [PubMed - indexed for MEDLINE]Related articles

The heat shock protein 90 chaperone complex: an evolving therapeutic target.

Barginear MF, Van Poznak C, Rosen N, Modi S, Hudis CA, Budman DR.

Curr Cancer Drug Targets. 2008 Sep;8(6):522-32. Review.PMID: 18781898 [PubMed - indexed for MEDLINE]Related articles

In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia.

Calabro A, Tai J, Allen SL, Budman DR.

Anticancer Drugs. 2008 Aug;19(7):705-12.PMID: 18594212 [PubMed - indexed for MEDLINE]Related articles

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD.

J Clin Oncol. 2008 May 10;26(14):2364-72. Epub 2008 Apr 7.PMID: 18390970 [PubMed - indexed for MEDLINE]Related articles

Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome.

Barginear MF, Lesser M, Akerman ML, Strakhan M, Shapira I, Bradley T, Budman DR.

Clin Appl Thromb Hemost. 2009 May-Jun;15(3):263-9. Epub 2008 Apr 1.PMID: 18385149 [PubMed - indexed for MEDLINE]Related articles

Implications of applied research for prognosis and therapy of breast cancer.

Barginear MF, Bradley T, Shapira I, Budman DR.

Crit Rev Oncol Hematol. 2008 Mar;65(3):223-34. Review.PMID: 18243013 [PubMed - indexed for MEDLINE]Related articles

Heparin-induced thrombocytopenia complicating hemodialysis.

Barginear MF, Donahue L, Allen SL, Budman DR, Bradley T, Bhaskaran M, Shapira I.

Clin Appl Thromb Hemost. 2008 Jan;14(1):105-7. Epub 2007 Dec 26.PMID: 18160608 [PubMed - indexed for MEDLINE]Related articles

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA; Cancer and Leukemia Group B Experience.

J Clin Oncol. 2007 Aug 20;25(24):3699-704.PMID: 17704418 [PubMed - indexed for MEDLINE]Related articles

Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.

Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, Xie Y, Zhang J, Chen Y, Budman DR, Shi YE.

Int J Cancer. 2007 Sep 15;121(6):1296-305.PMID: 17534899 [PubMed - indexed for MEDLINE]Related articles

A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.

Hirawat S, Kolitz J, Lichtman SM, Allen SL, Villani G, Gonzales A, Fricano M, Budman DR.

Cancer Invest. 2007 Apr-May;25(3):148-53.PMID: 17530484 [PubMed - indexed for MEDLINE]Related articles

Capecitabine-docetaxel combination treatment.

Mandelblat J, Bashir T, Budman DR.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1169-78. Review.PMID: 17020452 [PubMed - indexed for MEDLINE]Related articles

Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro.

Budman DR, Tai J, Calabro A.

Breast Cancer Res Treat. 2007 Jul;104(1):93-101. Epub 2006 Sep 27.PMID: 17004104 [PubMed - indexed for MEDLINE]Related articles

Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.

Budman DR, Soong R, Calabro A, Tai J, Diasio R.

Anticancer Drugs. 2006 Sep;17(8):921-8.PMID: 16940802 [PubMed - indexed for MEDLINE]Related articles

Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.

Budman DR, Calabro A.

Oncology. 2006;70(2):147-53. Epub 2006 Apr 26.PMID: 16645328 [PubMed - indexed for MEDLINE]Related articles

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP.

JAMA. 2006 Apr 12;295(14):1658-67. Erratum in: JAMA. 2006 May 24;295(20):2356. PMID: 16609087 [PubMed - indexed for MEDLINE]Related articlesFree article

Therapeutic index, tubulin binders, and clinical medicine.

Budman DR.

Cancer Invest. 2005;23(5):479-80. No abstract available. PMID: 16193646 [PubMed - indexed for MEDLINE]Related articles

Review: tubulin function, action of antitubulin drugs, and new drug development.

Pellegrini F, Budman DR.

Cancer Invest. 2005;23(3):264-73. Review.PMID: 15948296 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.

Schwartz GK, Weitzman A, O'Reilly E, Brail L, de Alwis DP, Cleverly A, Barile-Thiem B, Vinciguerra V, Budman DR.

J Clin Oncol. 2005 Aug 10;23(23):5365-73. Epub 2005 Jun 6.PMID: 15939925 [PubMed - indexed for MEDLINE]Related articles

Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.

Budman DR.

Semin Oncol. 2004 Dec;31(6 Suppl 15):3-9. Review.PMID: 15726532 [PubMed - indexed for MEDLINE]Related articles

Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.

Budman DR, Calabro A.

Anticancer Drugs. 2004 Oct;15(9):877-81.PMID: 15457128 [PubMed - indexed for MEDLINE]Related articles

Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells.

Liu XM, Jiang JD, Ferrari AC, Budman DR, Wang LG.

Br J Cancer. 2003 Oct 20;89(8):1566-73.PMID: 14562033 [PubMed - indexed for MEDLINE]Related articlesFree article

The androgen receptor: structure, mutations, and antiandrogens.

Hirawat S, Budman DR, Kreis W.

Cancer Invest. 2003 Jun;21(3):400-17. Review. Erratum in: Cancer Invest. 2003;21(6):960-2. PMID: 12901287 [PubMed - indexed for MEDLINE]Related articles

The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.

Lichtman SM, Etcubanas E, Budman DR, Eisenberg P, Zervos G, D'Amico P, O'Mara V, Musgrave K, Cascella P, Melikian A, Hinderling PH, Ferrer JM, Williams GJ.

Cancer Invest. 2002;20(7-8):904-13.PMID: 12449721 [PubMed - indexed for MEDLINE]Related articles

The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.

Budman DR.

Cancer Invest. 2002;20 Suppl 2:38-44. Review. No abstract available. PMID: 12442348 [PubMed - indexed for MEDLINE]Related articles

Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.

Budman DR, Calabro A, Kreis W.

Anticancer Drugs. 2002 Nov;13(10):1011-6.PMID: 12439335 [PubMed - indexed for MEDLINE]Related articles

New directions with capecitabine combinations in advanced breast cancer.

Budman DR.

Oncology (Williston Park). 2002 Oct;16(10 Suppl 12):23-8. Review.PMID: 12435176 [PubMed - indexed for MEDLINE]Related articles

In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.

Budman DR, Calabro A.

Breast Cancer Res Treat. 2002 Jul;74(1):41-6.PMID: 12150451 [PubMed - indexed for MEDLINE]Related articles

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.

Ann Oncol. 2002 Jun;13(6):903-9.PMID: 12123336 [PubMed - indexed for MEDLINE]Related articlesFree article

WTH3, a new member of the Rab6 gene family, and multidrug resistance.

Shan J, Yuan L, Budman DR, Xu HP.

Biochim Biophys Acta. 2002 Apr 3;1589(2):112-23.PMID: 12007787 [PubMed - indexed for MEDLINE]Related articles

Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.

Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson IC, Norton L, Hayes DF.

J Clin Oncol. 2002 Feb 1;20(3):732-42.PMID: 11821455 [PubMed - indexed for MEDLINE]Related articles

Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.

Liu XM, Wang LG, Kreis W, Budman DR, Adams LM.

Br J Cancer. 2001 Nov 2;85(9):1403-11.PMID: 11720482 [PubMed - indexed for MEDLINE]Related articlesFree article

In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?

Budman DR, Calabro A, Kreis W.

Leukemia. 2001 Oct;15(10):1517-20.PMID: 11587208 [PubMed - indexed for MEDLINE]Related articles

Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).

Lichtman SM, Kolitz J, Budman DR, Schulman P, Vinciguerra V, Hoffman M, Mittelman A, Allen SL, Fusco D, Hayes FA.

Am J Clin Oncol. 2001 Aug;24(4):360-2.PMID: 11474261 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.

Budman DR, Johnson R, Barile B, Bowsher RR, Vinciguerra V, Allen SL, Kolitz J, Ernest CS 2nd, Kreis W, Zervos P, Walling J.

Cancer Chemother Pharmacol. 2001 Jun;47(6):525-31.PMID: 11459206 [PubMed - indexed for MEDLINE]Related articles

A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents.

Kreis W, Budman DR, Calabro A.

Cancer Chemother Pharmacol. 2001;47(1):78-82.PMID: 11221966 [PubMed - indexed for MEDLINE]Related articles

Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.

Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, Kreis W.

Cancer Invest. 2000;18(8):695-701.PMID: 11107439 [PubMed - indexed for MEDLINE]Related articles

Capecitabine.

Budman DR.

Invest New Drugs. 2000 Nov;18(4):355-63. Review.PMID: 11081571 [PubMed - indexed for MEDLINE]Related articles

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L.

J Clin Oncol. 2000 Oct 15;18(20):3471-9.PMID: 11032587 [PubMed - indexed for MEDLINE]Related articles

The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.

Wang LG, Liu XM, Kreis W, Budman DR.

Cancer Chemother Pharmacol. 1999;44(5):355-61. Review.PMID: 10501907 [PubMed - indexed for MEDLINE]Related articles

Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells.

Wang LG, Liu XM, Budman DR, Kreis W.

Biochem Pharmacol. 1999 Oct 1;58(7):1115-21.PMID: 10484069 [PubMed - indexed for MEDLINE]Related articles

A phase I study of sequential vinorelbine followed by paclitaxel.

Budman DR, Weiselberg L, O'Mara V, Buchbinder A, Lichtman SM, Donahue L, Adams LM.

Ann Oncol. 1999 Jul;10(7):861-3.PMID: 10470436 [PubMed - indexed for MEDLINE]Related articlesFree article

RESPONSE: re: dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer

Berry DA, Budman DR.

J Natl Cancer Inst. 1999 Aug 18;91(16):1425A-1425. No abstract available. PMID: 10451458 [PubMed - as supplied by publisher]Related articlesFree article

Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.

Wang LG, Liu XM, Kreis W, Budman DR.

Biochem Biophys Res Commun. 1999 May 27;259(1):21-8.PMID: 10334909 [PubMed - indexed for MEDLINE]Related articles

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.

Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V.

Ann Oncol. 1999 Jan;10(1):33-8.PMID: 10076719 [PubMed - indexed for MEDLINE]Related articlesFree article

Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.

Wang LG, Liu XM, Kreis W, Budman DR.

Biochem Pharmacol. 1998 May 1;55(9):1427-33.PMID: 10076535 [PubMed - indexed for MEDLINE]Related articles

Acquired factor VIII inhibitors--successful treatment with an oral outpatient regimen.

Bayer RL, Lichtman SM, Allen SL, Budman DR, Buchbinder A, Fetten J, Kolitz J, Loscalzo J.

Am J Hematol. 1999 Jan;60(1):70-1.PMID: 9883809 [PubMed - indexed for MEDLINE]Related articles